Marshall Wace’s Tango Therapeutics TNGX Stock Holding History

Marshall Wace’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.47M	Buy	+174,909	New	+$4.32M	﹤0.01%	1328
2026 Q1	–	Sell	-329,231	Closed	-$2.92M	–	3678
2025 Q4	$2.92M	Sell	329,231 -1,160,287	-78%	-$10M	﹤0.01%	1400
2025 Q3	$12.5M	Sell	1,489,518 -253,173	-15%	-$1.71M	0.01%	835
2025 Q2	$8.92M	Sell	1,742,691 -99,472	-5%	-$246K	0.01%	890
2025 Q1	$2.52M	Buy	+1,842,163	New	+$4.52M	﹤0.01%	1370
2024 Q4	–	Sell	-73,122	Closed	-$563K	–	3009
2024 Q3	$563K	Buy	+73,122	New	+$698K	﹤0.01%	1878
2024 Q2	–	Sell	-109,269	Closed	-$868K	–	2965
2024 Q1	$868K	Buy	+109,269	New	+$1.17M	﹤0.01%	1711
2022 Q2	–	Sell	-28,915	Closed	-$220K	–	3847
2022 Q1	$220K	Buy	28,915 +22,646	+361%	+$196K	﹤0.01%	3069
2021 Q4	$68K	Buy	+6,269	New	+$75.4K	﹤0.01%	3485

Other funds holding TNGX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Marshall Wace's TNGX Position: Q2 2026 in Review

Marshall Wace opened a new position in Tango Therapeutics (TNGX) in Q2 2026: 174,909 shares worth $5.47M. The stake represents ﹤0.01% of the portfolio and ranks #1328 among its holdings. This is a return to the name: Marshall Wace previously reported a position in TNGX as recently as Q4 2025.

Marshall Wace first reported a position in TNGX in Q4 2021 and has held it in 9 quarters since. The position peaked at $12.5M in Q3 2025. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

Marshall Wace held 174,909 shares of Tango Therapeutics worth $5.47M as of Q2 2026.
Tango Therapeutics was a new Marshall Wace position in Q2 2026.
Tango Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1328 holding.
Marshall Wace first reported a position in Tango Therapeutics in Q4 2021 and has held it in 9 quarters since.
Marshall Wace's Tango Therapeutics position peaked at $12.5M in Q3 2025.
248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.